Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (Review)

Purpose: Polymeric nucleic acid drugs—plasmid DNA, antisense oligonucleotides, and ribozymes—require protection from nucleases and efficient intracellular delivery to cytoplasm/nucleus. Viral vectors are efficient but immunogenic and safety-limited; non-viral cationic lipid systems are promising, but the mechanism of endosomal escape and the specific role of phosphatidylethanolamine (PE) remain unclear.

Hypothesis: Lipid–nucleic acid particles enter target cells mainly by endocytosis, not direct plasma membrane fusion. Cationic lipids condense/pack polyanionic nucleic acids, while unsaturated PE—especially DOPE—destabilizes the endosomal bilayer through its preference for non-bilayer hexagonal H\(_{II}\) structures, disrupting the endosome and releasing nucleic acid into the cytoplasm. Fusogenic lipids/proteins enhance this endosomal release.

Aims: Review the role of cationic lipids and PE in condensation, particle formation, and transfection. - Discuss mechanisms of intracellular delivery: endocytosis, endosome disruption, lipid mixing/fusion, and cytoplasmic release. - Compare in vitro lipofection with in vivo systemic delivery, pharmacokinetics, and biodistribution. - Identify remaining barriers to clinical translation of lipid-based nucleic acid drugs.

Delivery system: Non-viral lipid carriers (“lipoplexes”): cationic lipids such as DODAC, DDAB, and related amphiphiles complexed with plasmid DNA, antisense oligonucleotides, or ribozymes. Helper lipid: unsaturated phosphatidylethanolamine, especially DOPE, acting as a fusogenic/non-bilayer-prone component. Some systems include viral fusion proteins (influenza hemagglutinin, adenovirus capsid, Sendai virus) or stabilizing lipids such as DOPC/PC and PEG shielding. Particles range from ~100 nm to >1 µm and typically carry a net positive charge.

Approach: Review article, not a primary experimental study. It synthesizes in vitro cell-culture transfection data, biophysical model-membrane studies, erythrocyte/ghost membrane interaction studies, and in vivo rodent biodistribution/gene-expression reports. No formal group structure, n, controls, or doses are reported as an original study.

Key methods: Ethidium bromide fluorescence for DNA condensation/charge neutralization. - Quasi-elastic light scattering for particle sizing. - Fluorescence energy transfer / lipid-mixing assays for membrane fusion. - Freeze-fracture electron microscopy for lipid–DNA particle and membrane structure. - \(^{31}\)P-NMR for lipid phase behavior. - Fluorescence microscopy for oligonucleotide uptake/nuclear accumulation. - Transfection/gene expression assays and in vivo pharmacokinetics/biodistribution.

Key results: DNA condensation occurs near charge neutralization; maximum in vitro transfection is near \(+/- \approx 1\), but in vivo formulations often use \(+/- >3\) to prevent aggregation. - Unsaturated PE alone adopts hexagonal H\(_{II}\); cationic lipids stabilize PE bilayers, but DNA/polyanions destabilize them, causing lipid mixing and aggregation. - Lipid–DNA particles are endocytosed; DOPE and viral fusogens enhance endosomal disruption and transfection. - Reconstituted influenza virosomes released >8% of contents into cytoplasm vs <0.01% for conventional liposomes; DODAC–DOPE complexes may approach virosome efficiency in unpublished data. - Fluorescent phosphorothioate oligonucleotides accumulated in nuclei within 2–4 h; plasmid nuclear entry is much less efficient. - In vivo IV lipid–DNA complexes show circulation half-lives of seconds to minutes, with clearance mainly by liver, then spleen/lung; high doses are needed and toxicity limits systemic use.

Interpretation: Cationic lipids are critical for electrostatic packaging of nucleic acids, but PE is proposed to be the key factor for endosomal membrane disruption and cytoplasmic release. Lipid–DNA delivery mimics some viral entry steps but remains far less efficient than viral vectors. Improved understanding of lipid mixing and non-bilayer intermediates should guide better non-viral vectors. Clinical intravenous use is not yet feasible until stability, serum resistance, toxicity, and potency are improved; regional/topical administration is more advanced.

Limitations: Review with no new primary data; some observations are unpublished. - Mechanisms of particle formation and endosome disruption are not well understood. - Conflicting reports on endosomal processing/lysosomotropic agents. - No clinical IV lipid-based gene delivery at the time. - Serum inhibits transfection; high doses cause toxicity. - Plasmid nuclear entry is a major bottleneck; long-term safety/efficacy unresolved.